[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 21, 1995

Cost of Patient Follow-up After Potentially Curative Colorectal Cancer Treatment

Author Affiliations

From the Department of Surgery, Saint Louis (Mo) University Health Sciences Center (Drs Virgo, Vernava, Longo, and Johnson), and Surgical Service, St Louis (Mo) Department of Veterans Affairs Medical Center (Drs Virgo, Longo, and Johnson and Mr McKirgan).

JAMA. 1995;273(23):1837-1841. doi:10.1001/jama.1995.03520470045030
Abstract

Objective.  —To estimate the cost of follow-up among colorectal cancer patients treated with curative intent based on the broad spectrum of surveillance strategies suggested in the literature.

Design.  —Economic analysis of the costs associated with 11 separate surveillance strategies. Charge data were obtained from the Part B Medicare Annual Data file and the Hospital Outpatient Bill file.

Setting.  —Ambulatory care.

Main Outcome Measures.  —Medicare-allowed charges and an actual-charge proxy for 5 years of follow-up after treatment for colorectal cancer patients on a nationwide basis.

Results.  —Medicare-allowed charges varied widely for the 5 years of posttreatment follow-up from a low of $561 to a high of $16 492. When Medicare-allowed charges were converted to a proxy for actual charges using a conversion ratio of 1.62, the range was $910 to $26 717, a 28-fold difference in charges.

Conclusions.  —Charges vary extensively across follow-up strategies, with no indication that higher-cost strategies increase survival or quality of life.(JAMA. 1995;273:1837-1841)

×